223 related articles for article (PubMed ID: 19509471)
1. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
Patel N; Krishnan S; Offman MN; Krol M; Moss CX; Leighton C; van Delft FW; Holland M; Liu J; Alexander S; Dempsey C; Ariffin H; Essink M; Eden TO; Watts C; Bates PA; Saha V
J Clin Invest; 2009 Jul; 119(7):1964-73. PubMed ID: 19509471
[TBL] [Abstract][Full Text] [Related]
2. Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
Rodrigues MAD; Pimenta MV; Costa IM; Zenatti PP; Migita NA; Yunes JA; Rangel-Yagui CO; de Sá MM; Pessoa A; Costa-Silva TA; Toyama MH; Breyer CA; de Oliveira MA; Santiago VF; Palmisano G; Barbosa CMV; Hebeda CB; Farsky SHP; Monteiro G
Biochem Pharmacol; 2020 Dec; 182():114230. PubMed ID: 32979352
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
[TBL] [Abstract][Full Text] [Related]
4. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
[TBL] [Abstract][Full Text] [Related]
5. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
6. Novel site-specific PEGylated L-asparaginase.
Meneguetti GP; Santos JHPM; Obreque KMT; Barbosa CMV; Monteiro G; Farsky SHP; Marim de Oliveira A; Angeli CB; Palmisano G; Ventura SPM; Pessoa-Junior A; de Oliveira Rangel-Yagui C
PLoS One; 2019; 14(2):e0211951. PubMed ID: 30753228
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
8. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
[TBL] [Abstract][Full Text] [Related]
9. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
10. A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native
Odaman Al I; Özdemir N; Zengin Ersoy G; Bayram C; Vupa Çilengiroğlu Ö; Arslantaş E; Paslı Uysalol E; Ayçiçek A
J Oncol Pharm Pract; 2023 Sep; 29(6):1454-1460. PubMed ID: 36942380
[TBL] [Abstract][Full Text] [Related]
11. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
12. A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro.
Maggi M; Mittelman SD; Parmentier JH; Colombo G; Meli M; Whitmire JM; Merrell DS; Whitelegge J; Scotti C
Sci Rep; 2017 Nov; 7(1):14479. PubMed ID: 29101342
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
[TBL] [Abstract][Full Text] [Related]
14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
15. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
17. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.
Gupta S; Wang C; Raetz EA; Schore R; Salzer WL; Larsen EC; Maloney KW; Mattano LA; Carroll WL; Winick NJ; Hunger SP; Loh ML; Devidas M
J Clin Oncol; 2020 Jun; 38(17):1897-1905. PubMed ID: 32275469
[TBL] [Abstract][Full Text] [Related]
18. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
19. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
Schnuchel A; Radcke C; Theobald L; Doeding S
PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
[TBL] [Abstract][Full Text] [Related]
20. In Silico Design of a Chimeric Humanized L-asparaginase.
Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
